Search company, investor...

Predict your next investment

Venture Capital
fprimecapital.com

Investments

486

Portfolio Exits

92

Funds

3

Partners & Customers

1

About F-Prime Capital

F-Prime Capital, formerly Fidelity Biosciences and Devonshire Investors, is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world's most significant challenges in healthcare and technology.

Headquarters Location

1 Main Street 13th Floor

Cambridge, Massachusetts, 02142,

United States

617-231-2400

Want to inform investors similar to F-Prime Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing F-Prime Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find F-Prime Capital in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing F-Prime Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned F-Prime Capital in 2 CB Insights research briefs, most recently on Feb 16, 2021.

Latest F-Prime Capital News

Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whole-Health Solutions for Subst...

Aug 30, 2023

Funding will expand company’s technology-enabled, alternate-payment care model, bringing its innovative and effective approach to more people in need BOSTON, August 29, 2023-- In its relentless pursuit of revolutionizing health outcomes for people with addictions, Better Life Partners (BLP), a virtual and in-person, community-embedded, whole-health solution for individuals and populations with substance use disorders (SUD), today announced the completion of a $26.5 million Series B funding round. Better Life Partners will use the new capital to further develop and scale its effective, technology-enabled care model for people with substance use disorders, while also expanding its population management services in new and existing markets. The round was co-led by aMoon, a global HealthTech fund, and existing investor F-Prime Capital, a global venture capital firm investing in healthcare and technology, with participation from existing investor, .406 Ventures, a top healthcare investor with deep expertise in building great businesses. Better Life Partners has raised $38 million since its founding in 2018 by Adam Groff MD and Steve Kelly. Unfortunately, millions of Americans today remain without true cost-effective access to addiction treatment, resulting in avoidable illness and, all too often, death. Better Life Partners uses a model that leverages community-embedded, high-access engagement, married with purpose-built technology and alternative-payment models, to drive effective and replicable outcomes across populations. The company offers a range of services to its members including specialty SUD treatment, mental and physical health care and care coordination, and is expanding into population health management. Currently operating in Maine, Massachusetts, New Hampshire, and Vermont, Better Life Partners has provided services to thousands of members, at least doubling engagement, retention, and continued treatment rates compared to standard options. “From the beginning, our mission has been simple and unwavering – to provide what it takes to heal from addiction, wherever, whenever,” said Juliana Ekong, MD, a public psychiatrist and the CEO of Better Life Partners. “Prioritizing those who have been denied true access to affordable, high-quality care, Better Life Partners offers an effective and replicable SUD solution that generates meaningful health and cost outcomes. With this endorsement from new and existing passionate health-tech investors, we are excited to dramatically accelerate and deepen the impact of our work.” “Better Life Partners is delivering tangible outcomes through an innovative healthtech model that is effective, scalable, and disruptive,” said Yair Schindel, MD, MBA, co-founder and managing partner of aMoon. “Its commitment to addressing the scourge of addictions with such a unique approach aligns with our vision of accelerating a cure for some of the world’s largest health challenges. BLP’s novel care delivery platform combined with its strong business model enables them to increase access and treat many patients struggling with SUDs in tandem and confront the large and growing SUD epidemic.” In conjunction with the latest funding, Dr. Yair Schindel (aMoon) has joined Better Life Partners’ Board of Directors, which includes Jon Lim (F-Prime Capital), Liam Donohue (.406 Ventures), Dr. Myechia Minter-Jordan (Independent) and Dr. Adam Groff, Better Life Partners’ co-founder. Continuing their tenure on the Better Life Partners’ leadership team are Steve Kelly, former U.S. Navy officer and formerly Chief Operating Officer, who will be stepping into the role of Chief Growth Officer, and Dr. David de Gijsel, internist and addictionologist, as Chief Health Officer. “We could not be more excited to partner with the team at aMoon to help scale BLP to the next level,” said Liam Donohue, Managing Partner of .406 Ventures and BLP director. “BLP has spent several years refining its uniquely effective approach to supporting those with substance use disorder and with the capital from this financing, we now have the resources to provide care to many more of those in need.” “The multi-specialty practice being developed by BLP is both a needed and novel approach to help people heal from addiction,” said Jon Lim, Partner at F-Prime Capital. “It has been exciting to be a part of the company’s rapid advancement and we look forward to continuing to support BLP’s leadership team in executing on its vital mission.” About aMoon A global fund based in Israel with over $1.3B AUM, aMoon leverages the pioneering scientific research, raw talent, and do-the-impossible culture of the Startup Nation. As Israel’s largest HealthTech VC fund, aMoon partners with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare and help people live better, healthier lives. aMoon invests across all stages of a company’s lifecycle through its three investment vehicles: aMoon Velocity, its early-stage fund, aMoon Growth, its mid-late-stage fund, and aMoon Edge its public equities fund. aMoon leverages its multidisciplinary team of over 50 scientists, physicians, and entrepreneurs, along with its robust network of investors and industry leaders, to build bridges between our portfolio companies and global HealthTech hubs as it helps entrepreneurs from the inception of an idea to the company launch. About F-Prime Capital F-Prime Capital is a global venture capital firm investing in healthcare and technology to solve the greatest challenges in health and medicine while delivering on the conviction that everyone deserves a gold standard of care. For over 50 years and with a portfolio of over 300 companies and counting spread across the Americas, Europe, and Asia, our independent venture capital group combines singular and deep expertise in life science, healthcare, and technology to identify and support founders with the next big ideas in therapeutics, medtech, and healthcare IT and services. With over $4.5 billion dollars under management, our team has created or co-created over 30 companies including Denali, Beam, Innovent, Orchard and Sana and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted Health, Prime Medicine and Ultragenyx. F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit www.fprimecapital.com and follow us on LinkedIn and X. About .406 Ventures .406 Ventures is a Boston-based early-stage venture capital firm with nearly two decades of experience investing in healthcare, AI, and enterprise technology companies founded by visionary entrepreneurs. The firm has over $1.4B under management. .406 leads, or co-leads, first institutional investment rounds backing the world’s best founders to build market-defining companies. Notable healthcare exits include Iora Health’s sale to One Medical/Amazon, AbleTo’s exit to Optum, Bend Financial’s sale to HSA Bank, and Health Dialog’s sale to BUPA. Learn more at 406ventures.com and follow us on LinkedIn and X. About Better Life Partners Better Life Partners is a multi-specialty solution for individuals and populations with substance use disorders. We provide care in a community-embedded and whole-health approach supported by alternative-payment models. The company provides on-site (in-person) and virtual care in the community forged with a trauma-informed, harm-reduction approach, while also supporting population level outcomes. Better Life Partners’ platform is purpose-built to succeed even with more complex populations and/or for populations for whom true and effective access is lacking. Committed to facilitating trusted care relationships that support belonging, love, and purpose, Better Life Partners improves health outcomes while decreasing overall health care costs. Better Life Partners is currently providing its addiction solution in New Hampshire, Maine, Vermont, and Massachusetts. It is contracted with Medicaid, Medicare, and most commercial insurers. Powered by a compassionate clinical team and backed by F-Prime Capital, .406 Ventures, aMoon, and other investors, Better Life Partners is providing what it takes to heal from addiction. Wherever, whenever. To learn more, visit https://betterlifepartners.com. Contact:

F-Prime Capital Investments

486 Investments

F-Prime Capital has made 486 investments. Their latest investment was in Equip Health as part of their Series D on September 9, 2023.

CBI Logo

F-Prime Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/19/2023

Series D

Equip Health

$20M

No

1

8/8/2023

Series D

Simon

$54M

No

2

8/4/2023

Series B

Rialtic

$36.71M

No

1

8/4/2023

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

8/2/2023

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/19/2023

8/8/2023

8/4/2023

8/4/2023

8/2/2023

Round

Series D

Series D

Series B

Series A - II

Series B

Company

Equip Health

Simon

Rialtic

Subscribe to see more

Subscribe to see more

Amount

$20M

$54M

$36.71M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

F-Prime Capital Portfolio Exits

92 Portfolio Exits

F-Prime Capital has 92 portfolio exits. Their latest portfolio exit was Neumora on September 15, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2023

IPO

$99M

Public

4

8/22/2023

Acquired

$99M

2

7/21/2023

IPO

$99M

Public

2

7/12/2023

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/3/2023

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2023

8/22/2023

7/21/2023

7/12/2023

2/3/2023

Exit

IPO

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

4

2

2

10

10

F-Prime Capital Acquisitions

1 Acquisition

F-Prime Capital acquired 1 company. Their latest acquisition was Citrine Medicine on January 01, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/1/2019

Series A

$99M

$80M

Acq - Fin

1

Date

1/1/2019

Investment Stage

Series A

Companies

Valuation

$99M

Total Funding

$80M

Note

Acq - Fin

Sources

1

F-Prime Capital Fund History

3 Fund Histories

F-Prime Capital has 3 funds, including Fidelity Biosciences.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Fidelity Biosciences

Early-Stage Venture Capital

Closed

1

Fidelity Biosciences Fund II

Subscribe to see more

Subscribe to see more

10

Beacon Bioventures Fund III LP

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

Fidelity Biosciences

Fidelity Biosciences Fund II

Beacon Bioventures Fund III LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

Sources

1

10

10

F-Prime Capital Partners & Customers

1 Partners and customers

F-Prime Capital has 1 strategic partners and customers. F-Prime Capital recently partnered with Atlas on October 10, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

10/21/2014

Partner

United States

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field .

1

Date

10/21/2014

Type

Partner

Business Partner

Country

United States

News Snippet

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field .

Sources

1

F-Prime Capital Team

8 Team Members

F-Prime Capital has 8 team members, including current President, Managing Partner, Stephen Knight.

Name

Work History

Title

Status

Stephen Knight

President, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Stephen Knight

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.